Cover Image

Secondary hematological malignancies following breast cancer treatment

Soley Bayraktar, Maricer P. Escalon
  • Soley Bayraktar
    Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, United States | sbayraktar@med.miami.edu
  • Maricer P. Escalon
    Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, United States

Abstract

Breast cancer (BC) incidence has increased among women in most Western countries. Concurrently, the survival time of BC patients has increased with 5-year survival rates reaching 80–90%. Secondary hematological malignancies (SHM) following BC treatment are an issue of concern to clinicians and also to patients and their families. However, therapy-induced leukemia after BC is an underemphasized clinical problem. In this review,we will focus on the incidences and patterns of occurrence ofSHM in patients with BC. We will address risk factors for the development of SHM and we will explore how secondary hematological malignancies impact the survival of BC patients.

Keywords

Breast cancer - Chemotherapy - Leukemia - Secondary hematological malignancies

Full Text:

FULL TEXT
Submitted: 2011-12-05 11:14:36
Published: 2011-12-05 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
449

Views:
FULL TEXT
179

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Soley Bayraktar, Maricer P. Escalon

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185